Page 33 - Read Online

Moreno-Martínez et al. Rare Dis Orphan Drugs J 2024;3:9 https://dx.doi.org/10.20517/rdodj.2023.51 Page 13 of 16

expression in Fabry disease endothelial cells. Mol Genet Metab 2008;95:163-8. DOI PubMed PMC
35. Park S, Kim JA, Joo KY, et al. Globotriaosylceramide leads to K 3.1 channel dysfunction: a new insight into endothelial dysfunction
Ca
in Fabry disease. Cardiovasc Res 2011;89:290-9. DOI PubMed
36. Choi S, Kim JA, Na HY, et al. Globotriaosylceramide induces lysosomal degradation of endothelial K 3.1 in fabry disease.
Ca
Arterioscler Thromb Vasc Biol 2014;34:81-9. DOI PubMed
37. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A
2008;105:2812-7. DOI PubMed PMC
38. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE. Vasculopathy in patients with Fabry disease: current
controversies and research directions. Mol Genet Metab 2010;99:99-108. DOI PubMed
39. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme
inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007;21:20-7. DOI PubMed
40. Cavanagh EM, Ferder M, Inserra F, Ferder L. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an
integrating viewpoint. Am J Physiol Heart Circ Physiol 2009;296:H550-8. DOI PubMed
41. Mishra V, Banerjee A, Gandhi AB, et al. Stroke and Fabry disease: a review of literature. Cureus 2020;12:e12083. DOI PubMed
PMC
42. Lam YLT, Sheng B, Kwok HM, Yu ELM, Ma KFJ. Basilar artery diameter as neuroimaging biomarker in Chinese Fabry disease
patients. Orphanet J Rare Dis 2023;18:186. DOI PubMed PMC
43. Uçeyler N, Homola GA, Guerrero González H, et al. Increased arterial diameters in the posterior cerebral circulation in men with
Fabry disease. PLoS One 2014;9:e87054. DOI PubMed PMC
44. Fellgiebel A, Keller I, Martus P, et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients.
Cerebrovasc Dis 2011;31:294-9. DOI PubMed
45. Pico F, Labreuche J, Touboul PJ, Leys D, Amarenco P. Intracranial arterial dolichoectasia and small-vessel disease in stroke patients.
Ann Neurol 2005;57:472-9. DOI PubMed
46. Zhang DP, Yin S, Zhang HL, Li D, Song B, Liang JX. Association between intracranial arterial dolichoectasia and cerebral small
vessel disease and its underlying mechanisms. J Stroke 2020;22:173-84. DOI PubMed PMC
47. Mehta A, Clarke JT, Giugliani R, et al; FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in
FOS - Fabry Outcome Survey. J Med Genet 2009;46:548-52. DOI PubMed
48. Hagège A, Réant P, Habib G, et al. Fabry disease in cardiology practice: Literature review and expert point of view. Arch Cardiovasc
Dis 2019;112:278-87. DOI PubMed
49. Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease:
potential implications for the time course of the disease. Eur Heart J 2005;26:1221-7. DOI PubMed
50. Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, Osterziel KJ. The heart in Anderson Fabry disease. Z Kardiol 2002;91:786-
95. DOI PubMed
51. Weidemann F, Maier SKG, Störk S, et al. Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in
patients with advanced Fabry cardiomyopathy. Am J Cardiol 2016;118:264-74. DOI PubMed
52. Beck M, Cox TM. Comment: why are females with Fabry disease affected? Mol Genet Metab Rep 2019;21:100529. DOI PubMed
PMC
53. Fuller M, Mellett N, Hein LK, Brooks DA, Meikle PJ. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured
skin fibroblasts. Mol Genet Metab 2015;114:268-73. DOI PubMed
54. Dobyns WB, Filauro A, Tomson BN, et al. Inheritance of most X-linked traits is not dominant or recessive, just X-linked. Am J Med
Genet A 2004;129A:136-43. DOI PubMed
55. Kolodny E, Fellgiebel A, Hilz MJ, et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke
2015;46:302-13. DOI PubMed
56. Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996;40:8-17. DOI PubMed
57. Mehta A, Hughes DA. Fabry disease. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1292/. [Last accessed on 21 March
2024].
58. Morgan SH, Rudge P, Smith SJ, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)
- investigation of symptomatic and presymptomatic patients. Q J Med 1990;75:491-507. PubMed
59. Grewal RP. Stroke in Fabry’s disease. J Neurol 1994;241:153-6. DOI PubMed
60. Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI
retrospective study. J Neurol Neurosurg Psychiatry 2008;79:1249-54. DOI PubMed
61. Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G. Clinical features of Fabry’s disease in Australian patients. Intern
Med J 2002;32:575-84. DOI PubMed
62. Vedder AC, Linthorst GE, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb levels. J
3
Inherit Metab Dis 2007;30:68-78. DOI PubMed
63. Utsumi K, Ueda K, Watanabe M, et al. Thrombosis in Japanese patients with Fabry disease. J Neurol Sci 2009;283:83-5. DOI
PubMed
64. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60
obligate carrier females. J Med Genet 2001;38:769-75. DOI PubMed PMC